Group One Trading’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-213,700
| Closed | -$8.41M | – | 8666 |
|
|
2023
Q2 | $8.41M | Buy |
213,700
+135,000
| +172% | +$4.77M | 0.03% | 608 |
|
|
2023
Q1 | $1.91M | Sell |
78,700
-65,900
| -46% | -$1.44M | 0.01% | 1566 |
|
|
2022
Q4 | $3.1M | Sell |
144,600
-78,500
| -35% | -$1.68M | 0.01% | 1467 |
|
|
2022
Q3 | $4M | Buy |
223,100
+154,300
| +224% | +$2.03M | 0.01% | 1341 |
|
|
2022
Q2 | $662K | Buy |
68,800
+47,500
| +223% | +$596K | ﹤0.01% | 3164 |
|
|
2022
Q1 | $358K | Buy |
21,300
+12,200
| +134% | +$180K | ﹤0.01% | 4196 |
|
|
2021
Q4 | $152K | Sell |
9,100
-899,500
| -99% | -$14.7M | ﹤0.01% | 5366 |
|
|
2021
Q3 | $14.8M | Buy |
908,600
+900,500
| +11,117% | +$9.8M | 0.02% | 792 |
|
|
2021
Q2 | $51K | Sell |
8,100
-5,800
| -42% | -$37.4K | ﹤0.01% | 6569 |
|
|
2021
Q1 | $86K | Sell |
13,900
-40,300
| -74% | -$245K | ﹤0.01% | 5799 |
|
|
2020
Q4 | $375K | Sell |
54,200
-36,900
| -41% | -$236K | ﹤0.01% | 3528 |
|
|
2020
Q3 | $514K | Buy |
91,100
+69,300
| +318% | +$330K | ﹤0.01% | 2819 |
|
|
2020
Q2 | $111K | Buy |
21,800
+19,800
| +990% | +$82.5K | ﹤0.01% | 3824 |
|
|
2020
Q1 | $7K | Sell |
2,000
-4,400
| -69% | -$25.7K | ﹤0.01% | 4702 |
|
|
2019
Q4 | $55K | Buy |
+6,400
| New | +$22.9K | ﹤0.01% | 3966 |
|
|
2019
Q1 | – | Sell |
-2,400
| Closed | -$3K | – | 5526 |
|
|
2018
Q4 | $3K | Sell |
2,400
-25,000
| -91% | -$48.4K | ﹤0.01% | 4612 |
|
|
2018
Q3 | $65K | Hold |
27,400
| – | – | ﹤0.01% | 3820 |
|
|
2018
Q2 | $75K | Buy |
27,400
+22,000
| +407% | +$60.7K | ﹤0.01% | 3727 |
|
|
2018
Q1 | $15K | Sell |
5,400
-6,000
| -53% | -$17.4K | ﹤0.01% | 4195 |
|
|
2017
Q4 | $36K | Buy |
11,400
+3,000
| +36% | +$8.43K | ﹤0.01% | 3896 |
|
|
2017
Q3 | $24K | Sell |
8,400
-4,500
| -35% | -$12.2K | ﹤0.01% | 3990 |
|
|
2017
Q2 | $33K | Sell |
12,900
-8,200
| -39% | -$22.3K | ﹤0.01% | 3728 |
|
|
2017
Q1 | $77K | Sell |
21,100
-416,400
| -95% | -$1.76M | ﹤0.01% | 3139 |
|
|
2016
Q4 | $2.11M | Buy |
437,500
+344,800
| +372% | +$10.2M | 0.02% | 889 |
|
|
2016
Q3 | $4.28M | Buy |
92,700
+67,800
| +272% | +$3.82M | 0.05% | 480 |
|
|
2016
Q2 | $1.27M | Buy |
24,900
+23,500
| +1,679% | +$1.17M | 0.02% | 1102 |
|
|
2016
Q1 | $59K | Sell |
1,400
-2,300
| -62% | -$117K | ﹤0.01% | 3165 |
|
|
2015
Q4 | $291K | Sell |
3,700
-13,100
| -78% | -$757K | ﹤0.01% | 2226 |
|
|
2015
Q3 | $681K | Buy |
16,800
+1,800
| +12% | +$95.4K | 0.01% | 1536 |
|
|
2015
Q2 | $781K | Sell |
15,000
-5,900
| -28% | -$294K | 0.01% | 1420 |
|
|
2015
Q1 | $972K | Buy |
20,900
+13,300
| +175% | +$690K | 0.02% | 1109 |
|
|
2014
Q4 | $341K | Sell |
7,600
-10,600
| -58% | -$445K | 0.01% | 1848 |
|
|
2014
Q3 | $709K | Sell |
18,200
-8,500
| -32% | -$334K | 0.01% | 1347 |
|
|
2014
Q2 | $1.13M | Buy |
26,700
+7,500
| +39% | +$275K | 0.02% | 1053 |
|
|
2014
Q1 | $686K | Buy |
19,200
+17,400
| +967% | +$587K | 0.01% | 1391 |
|
|
2013
Q4 | $58K | Buy |
+1,800
| New | +$53.4K | ﹤0.01% | 3497 |
|
Group One Trading's ISEE Position: Q2 2023 in Review
Group One Trading sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q2 2023, closing a stake of 1,712 shares — an estimated $60.4K sold.
Group One Trading first reported a position in ISEE in Q4 2013 and held it in 21 quarters. The position peaked at $4.46M in Q3 2022. 256 funds tracked by Wall St. Rank hold ISEE as of Q2 2023.
- Group One Trading reported no remaining IVERIC bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Group One Trading sold 1,712 IVERIC bio, Inc. Common Stock shares in Q2 2023, an estimated $60.4K.
- Group One Trading first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 21 quarters.
- Group One Trading's IVERIC bio, Inc. Common Stock position peaked at $4.46M in Q3 2022.
- 256 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q2 2023.
Based on Group One Trading's 13F filing for Q2 2023, filed 9 Aug 2023.